Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Overview Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Companies Involved in Therapeutics Development BLR Bio LLC FibroGen Inc ProMetic Life Sciences Inc RXi Pharmaceuticals Corp Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Drug Profiles BLR-100 - Drug Profile Product Description Mechanism Of Action R&D Progress BLR-200 - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy to Target SOD2 and CTGF for Radiation Toxicity - Drug Profile Product Description Mechanism Of Action R&D Progress IB-DMD - Drug Profile Product Description Mechanism Of Action R&D Progress OLX-101 - Drug Profile Product Description Mechanism Of Action R&D Progress OLX-201 - Drug Profile Product Description Mechanism Of Action R&D Progress OLX-301D - Drug Profile Product Description Mechanism Of Action R&D Progress OLX-701 - Drug Profile Product Description Mechanism Of Action R&D Progress pamrevlumab - Drug Profile Product Description Mechanism Of Action R&D Progress PBI-4050 - Drug Profile Product Description Mechanism Of Action R&D Progress RXI-109 - Drug Profile Product Description Mechanism Of Action R&D Progress Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Dormant Products Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Discontinued Products Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Product Development Milestones Featured News & Press Releases Mar 01, 2018: Fibrogen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer Feb 16, 2018: Prometic Announces Publication of PBI-4050's Novel Antifibrotic Mechanism of Action in American Journal of Pathology Jan 29, 2018: Prometics PBI-4050: Phase 3 Pivotal Clinical Trial Design For Idiopathic Pulmonary Fibrosis (IPF) Finalized Dec 18, 2017: RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with RXI-109 for Dermal Scarring Dec 11, 2017: Prometic's PBI-4050 Receives Promising Innovative Medicine (PIM) Designation From The UK MHRA In The Treatment Of Idiopathic Pulmonary Fibrosis Oct 25, 2017: Prometic Receives Fast Track Designation for PBI-4050 in Development for Idiopathic Pulmonary Fibrosis Oct 20, 2017: Prometic Presents PBI-4050 in Vivo Data at American Association for the Study of Liver Diseases (AASLD) Meeting Sep 25, 2017: Prometic receives FDA clearance of its IND to initiate pivotal PBI-4050 Phase 2/3 trial in patients with idiopathic pulmonary fibrosis Sep 19, 2017: Prometic Reports Positive Clinical Data from Ongoing PBI-4050 Study in Alstrom Syndrome Patients Sep 13, 2017: Fibrogen Presents Latest Data From Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at European Respiratory Society International Congress 2017 Sep 05, 2017: FibroGen Announces Pamrevlumab Oral and Poster Presentations at European Respiratory Society International Congress 2017 Aug 07, 2017: FibroGen Announces Positive Topline Results from Phase 2 Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis Jun 21, 2017: FibroGen Granted Orphan Drug Designation for Pamrevlumab in the Treatment of Pancreatic Cancer Jun 21, 2017: RXi Pharmaceuticals Announces Completion of Enrollment of Phase 1/2 Clinical Trial with RXI-109 for Retinal Scarring Jun 12, 2017: New data presented by Prometic at ADA's Scientific Sessions validates PBI-4050's positive impact on kidneys in patients with diabetes and metabolic syndrome Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Indications, H1 2018 Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018 Number of Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 (Contd..1), H1 2018 Number of Products under Investigation by Universities/Institutes, H1 2018 Products under Investigation by Universities/Institutes, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Pipeline by BLR Bio LLC, H1 2018 Pipeline by FibroGen Inc, H1 2018 Pipeline by ProMetic Life Sciences Inc, H1 2018 Pipeline by RXi Pharmaceuticals Corp, H1 2018 Dormant Products, H1 2018 Dormant Products, H1 2018 (Contd..1), H1 2018 Discontinued Products, H1 2018List of Figures Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Top 10 Indications, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Molecule Types, H1 2018 Number of Products by Stage and Molecule Types, H1 2018